Covid-19 roundup: CDC study con­firms re­al-world ef­fi­ca­cy of mR­NA shots; In­dia ex­port lim­its de­lay CO­V­AX ship­ments

A new re­al-world study from the CDC con­firms the high ef­fi­ca­cy lev­els and pro­tec­tive ben­e­fits of mR­NA Covid-19 vac­cines, the agency an­nounced Mon­day.

Vac­cines de­vel­oped by Pfiz­er/BioN­Tech and Mod­er­na re­duced the risk of in­fec­tion by 80% with­in two weeks af­ter tak­ing just one shot, the study said. That rate rose to 90% two weeks fol­low­ing the sec­ond sched­uled vac­ci­na­tion.

The study com­prised near­ly 4,000 health care per­son­nel, first re­spon­ders, and oth­er es­sen­tial work­ers across six states. Re­searchers looked at da­ta from Dec. 14 to March 13.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER